569 A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patients

Authors :: Jeffrey Houlton
Daniel Clayburgh
Ryan Li
Nathan Schauer
Marc Grenley
Connor Burns
Angela Merrell
Jason Frazier
Jonathan Derry
Emily Beirne
Wendy Jenkins
Allison Berger
Richard Klinghoffer
Source :: Regular and Young Investigator Award Abstracts.
Publication Year :: 2022
Publisher :: BMJ Publishing Group Ltd, 2022.

Full Text Access

Tools